Sano Genetics Raises $11.4M to Enhance Precision Medicine Platform
Sano Genetics, a Cambridge, UK-based provider of a software platform for precision medicine clinical trials, recently secured $11.4M in funding. Led by Plural, this funding round brings the company's total amount raised to $22M. The investment will be used to further automate Sano Genetics' processes, enhancing the efficiency of their platform.
Founded by Patrick Short (CEO), Charlotte Guzzo (COO), and William Jones (CTO), Sano Genetics is focused on developing software that enables precision medicine.
Their platform seamlessly integrates genetic testing, recruitment, and long-term patient engagement, streamlining operations for precision medicine teams and patients. By connecting patients from multiple countries with pharmaceutical and biotech companies conducting clinical trials, Sano Genetics facilitates easier access to precision medical treatment.
Sano Genetics collaborates with pharmaceutical companies, biotechs, researchers, and patient advocacy groups to drive efficient and impactful research. The company specializes in finding, screening, and engaging trial participants, resulting in faster and more cost-effective trials. With this latest funding, Sano Genetics aims to integrate LLMs and other AI tools, boosting productivity and supporting their growth trajectory.
They've invested in Sano Genetics
Get to know these Healthtech investors
Click here for a full list of 7,526+ startup investors in the UK